VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

MannKind Executive Compensation (FY25)

MNKD · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Michael Castagna
Latest say-on-pay support
=
May 20, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The MannKind brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): May 22, 2026
14 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
MannKind brief$500Get the executive brief
Velarion Intel, one year, every company
308 figures on this page: 298 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Michael Castagna: $9,490,628 → $9,300,485 (2.0% lower)
Say-on-pay support: 91.9% → 89.4% (2.5 points lower)
CEO pay ratio: 54:1 → 46:1 (14.8% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is MannKind's chief executive and what were they paid?
Michael Castagna, Chief Executive Officer, received $9,300,485 in total compensation for fiscal 2025. Castagna's total was 2.0% lower than the $9,490,628 reported for fiscal 2024.
What was MannKind's say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 89.4% of votes cast for or against in favor at the meeting held May 20, 2026.
Which companies are in MannKind's peer group?
Companies named in the disclosed peer group include ADMA Biologics, Inc. and Travere Therapeutics, Inc.
What is MannKind's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 46:1, against median employee compensation of $203,592.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Castagna
Chief Executive Officer
◇—◇—◇—◇◇
Steven Binder
Former Chief Financial Officer
◇—◇—◇—◇◇
David Thomson
EVP, General Counsel and Secretary
◇—◇—◇—◇◇
Stuart Tross
EVP, Chief People and Workplace Officer
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Castagna
Chief Executive Officer
◇—◇—◇—◇◇
David Thomson
EVP, General Counsel and Secretary
◇—◇—◇—◇◇
Steven Binder
Former Chief Financial Officer
◇—◇—◇—◇◇
Stuart Tross
EVP, Chief People and Workplace Officer
◇—◇—◇—◇◇
Lauren Sabella
EVP, Chief Operating Officer
◇—◇—◇—◇◇
Burkhard Blank
EVP, Chief Medical Officer
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Castagna
Chief Executive Officer
◇—◇—◇—◇◇
Christopher Prentiss
Chief Financial Officer
◇—◇—◇—◇◇
David Thomson
EVP, General Counsel and Secretary
◇—◇—◇—◇◇
Lauren Sabella
EVP, Chief Operating Officer
◇—◇—◇—◇◇
Burkhard Blank
EVP, Chief Medical Officer
◇—◇—◇—◇◇
Steven Binder
Former Chief Financial Officer
Departed during or after this year
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Castagna
Chief Executive Officer
◇—◇—◇—◇◇
Dominic Marasco
President, Endocrine Business Unit
◇—◇—◇—◇◇
David Thomson
Executive Vice President, General Counsel and Secretary
◇—◇—◇—◇◇
Stuart Tross
Executive Vice President, Human Resources
◇—◇—◇—◇◇
Christopher Prentiss
Chief Financial Officer
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christopher B. PrentissPSU◇◇◇—◇—◇
Christopher B. PrentissRSU◇——◇——◇
David B. ThomsonPSU◇◇◇—◇—◇
David B. ThomsonRSU◇——◇——◇
Dominic MarascoRSU◇——◇——◇
Dominic MarascoRSU◇——◇——◇
Dominic MarascoRSU◇——◇——◇
Dominic MarascoPSU◇◇◇—◇—◇
Michael E. CastagnaPSU◇◇◇—◇—◇
Michael E. CastagnaRSU◇——◇——◇
Stuart TrossPSU◇◇◇—◇—◇
Stuart TrossRSU◇——◇——◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Dominic MarascoPSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Michael CastagnaPSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Stuart TrossPSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
David ThomsonPSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Christopher PrentissPSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Christopher Prentiss
Chief Financial Officer · Change-in-control agreement
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
David Thomson
Executive Vice President, General Counsel and Secretary · Employment agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Excise tax treatment◇
Dominic Marasco
President, Endocrine Business Unit · Change-in-control agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Michael Castagna
Chief Executive Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Stuart Tross
Executive Vice President, Human Resources · Change-in-control agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James S. Shannon
Board chair
◇◇————◇
Ronald J. Consiglio
◇◇————◇
Anthony Hooper
◇◇————◇
Jennifer Grancio
◇◇————◇
Sabrina Kay
◇◇————◇
Christine Mundkur
◇◇————◇
Michael A. Friedman
◇◇————◇
Steven B. Binder
◇◇————◇
Michael E. Castagna served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ADMA Biologics, Inc. ADMA
  • Travere Therapeutics, Inc. TVTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 20, 2026=◇◇◇
2024May 14, 2025=◇◇◇
2023May 15, 2024=◇◇◇
2022May 25, 2023=◇◇◇
2021May 10, 2022=◇◇◇
2020May 20, 2021=◇◇◇
2019May 21, 2020=◇◇◇
2018May 14, 2019=◇◇◇
2017May 16, 2018=◇◇◇
2015May 19, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Michael Castagna (Chief Executive Officer), FY2025 total compensation $9,300,485 (base salary $789,436) [exec_comp, SEC accession 0001193125-26-145613, filed 2026-04-07]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when MannKind files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact MannKind disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where MannKind sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether MannKind's disclosed peer group is defensible, who names MannKind back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
308 figures on this page: 298 cited to the filing that reported them, 10 calculated from figures it prints.
298 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001193125-26-237183
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-145613
    CEO Pay Ratio · COMPENSATION OF DIRECTORS · Compensation Table · Director Compensation · and 3 more sections
  3. 0000950170-25-074523
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000950170-25-048683
  5. 0000950170-24-061164
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000950170-24-042052
  7. 0001193125-23-156575
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001564590-22-019928
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001193125-21-171623
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-20-153051
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001193125-19-147997
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-18-166685
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001193125-16-600626
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “MannKind executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/MNKD (accessed 2026).
Short form: data: Velarion

The MannKind brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about MannKind and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers MannKind discloses

The companies named in MNKD's own disclosed peer group.

ADMA Biologics, Inc.Travere Therapeutics, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy